Comparison of Optical Coherence Tomography Biomarkers between Bevacizumab Good Responders and Nonresponders Who were Switched to Dexamethasone Implant in Diabetic Macular Edema
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To compare volumetric optical coherence tomography (OCT) biomarkers in bevacizumab responsive and bevacizumabrefractory diabetic macular edema (DME) patients switched to the dexamethasone implant to ultimately identify possibleprognostic indicators. Methods: Retrospective analysis of DME patients treated with bevacizumab were done. Patients were divided into thosewho showed response to bevacizumab (bevacizumab only group) and others who were switched to the dexamethasone implantdue to lack of response to bevacizumab (switching group). Volumetric OCT biomarkers such as central macular thickness(CMT), inner and outer cystoid macular edema (CME) volume, serous retinal detachment (SRD) volume, retinal volume (CME+ SRD volume) within the 6-mm Early Treatment of Diabetic Retinopathy Study circle were calculated. OCT biomarkers werefollowed up throughout treatment. Results: Among total of 144 eyes, 113 patients were included in the bevacizumab only group and 31 patients were includedin the switching group. Compared to the bevacizumab only group, the switching group showed higher baseline CMT (558.00± 209.60 μm vs. 454.96 ± 125.88 μm, p = 0.003), larger inner CME (6.02 ± 1.43 mm3 vs. 5.12 ± 0.87 mm3, p = 0.004) and SRDvolume (0.32 ± 0.40 mm3 vs. 0.11 ± 0.09 mm3, p = 0.015) and higher proportion of patients with SRD (58.06% vs. 31.86%, p =0.008). In the switching group, CMT, inner CME and SRD volume all showed significant reduction after switching to the dexamethasoneimplant. Conclusions: DME with large SRD and inner nuclear layer edema volume may be more effectively treated with the dexamethasoneimplant than bevacizumab.
Abstract
Purpose: To compare volumetric optical coherence tomography (OCT) biomarkers in bevacizumab responsive and bevacizumabrefractory diabetic macular edema (DME) patients switched to the dexamethasone implant to ultimately identify possibleprognostic indicators. Methods: Retrospective analysis of DME patients treated with bevacizumab were done. Patients were divided into thosewho showed response to bevacizumab (bevacizumab only group) and others who were switched to the dexamethasone implantdue to lack of response to bevacizumab (switching group). Volumetric OCT biomarkers such as central macular thickness(CMT), inner and outer cystoid macular edema (CME) volume, serous retinal detachment (SRD) volume, retinal volume (CME+ SRD volume) within the 6-mm Early Treatment of Diabetic Retinopathy Study circle were calculated. OCT biomarkers werefollowed up throughout treatment. Results: Among total of 144 eyes, 113 patients were included in the bevacizumab only group and 31 patients were includedin the switching group. Compared to the bevacizumab only group, the switching group showed higher baseline CMT (558.00± 209.60 μm vs. 454.96 ± 125.88 μm, p = 0.003), larger inner CME (6.02 ± 1.43 mm3 vs. 5.12 ± 0.87 mm3, p = 0.004) and SRDvolume (0.32 ± 0.40 mm3 vs. 0.11 ± 0.09 mm3, p = 0.015) and higher proportion of patients with SRD (58.06% vs. 31.86%, p =0.008). In the switching group, CMT, inner CME and SRD volume all showed significant reduction after switching to the dexamethasoneimplant. Conclusions: DME with large SRD and inner nuclear layer edema volume may be more effectively treated with the dexamethasoneimplant than bevacizumab.
참고문헌 (33)
- Williams R, "Epidemiology of diabetic retinopathy and macular oedema: a systematic review", Eye(Lond), 18, pp.963~983 (2004)
- Moss SE, "The 14-year incidence of visual loss in a diabetic population", Ophthalmology, 105, pp.998~1003 (1998)
- Klaassen I, "Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions", Prog Retin Eye Res, 34, pp.19~48 (2013)
- Haller JA, "Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema", Arch Ophthalmol, 128, pp.289~296 (2010)
- Otani T, "Patterns of diabetic macular edema with optical coherence tomography", Am J Ophthalmol, 127, pp.688~693 (1999)
- Kim BY, "Optical coherence tomographic patterns of diabetic macular edema", Am J Ophthalmol, 142, pp.405~412 (2006)
- Sonoda S, "Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema", Retina, 34, pp.741~748 (2014)
- Vujosevic S, "Diabetic macular edema with and without subfoveal neuroretinal detachment : two different morphologic and functional entities", Am J Ophthalmol, 181, pp.149~155 (2017)
- Daruich A, "Mechanisms of macular edema : beyond the surface", Prog Retin Eye Res, 63, pp.20~68 (2018)
- Seo KH, "Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns", Retina, 36, pp.588~595 (2016)
- Hu Y, "Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography", Graefes Arch Clin Exp Ophthalmol, 257, pp.2613~2621 (2019)
- Castro-Navarro V, "Intravitreal dexamethasone implant Ozurdex in naïve and refractory patients with different subtypes of diabetic macular edema", BMC Ophthalmol, 19, pp.15~ (2019)
- Bayat AH, "Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema", Ther Adv Ophthalmol, 12, pp.2515841420971936~ (2020)
- Ceravolo I, "The application of structural retinal biomarkers to evaluate the effect of intravitreal ranibizumab and dexamethasone intravitreal implant on treatment of diabetic macular edema", Diagnostics(Basel), 10, pp.413~ (2020)
- Bonfiglio V, "Dexamethasone for unresponsive diabetic macular oedema : optical coherence tomography biomarkers", Acta Ophthalmol, 97, pp.e540~4 (2019)
- van Dijk HW, "Early neurodegeneration in the retina of type 2 diabetic patients", Invest Ophthalmol Vis Sci, 53, pp.2715~2719 (2012)
- Chhablani J, "Neurodegeneration in type 2 diabetes : evidence from spectral-domain optical coherence tomography", Invest Ophthalmol Vis Sci, 56, pp.6333~6338 (2015)
- Ebneter A, "Retinal layer response to ranibizumab during treatment of diabetic macular edema : thinner is not always better", Retina, 36, pp.1314~1323 (2016)
- Kim M, "Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema", Ophthalmologica, 226, pp.138~144 (2011)
- Shimura M, "Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema", Retina, 33, pp.740~747 (2013)
- Ozdemir H, "Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema", Am J Ophthalmol, 140, pp.251~255 (2005)
- Demircan A, "Comparison of the effect of ranibizumab and dexamethasone implant on serous retinal detachment in diabetic macular edema", J Fr Ophtalmol, 41, pp.733~738 (2018)
- Antcliff RJ, "Hydraulic conductivity of fixed retinal tissue after sequential excimer laser ablation : barriers limiting fluid distribution and implications for cystoid macular edema", Arch Ophthalmol, 119, pp.539~544 (2001)
- Provis JM, "Development of the primate retinal vasculature", Prog Retin Eye Res, 20, pp.799~821 (2001)
- Snodderly DM, "Neural-vascular relationships in central retina of macaque monkeys(Macaca fascicularis)", J Neurosci, 12, pp.1169~1193 (1992)
- Elnahry AG, "Optical coherence tomography angiography biomarkers predict anatomical response to bevacizumab in diabetic macular edema", Diabetes Metab Syndr Obes, 15, pp.395~405 (2022)
- Hodzic-Hadzibegovic D, "Diabetic macular edema treated with anti-vascular endothelial growth factor : considerations related to nonimprovers", Ophthalmol Retina, 2, pp.1133~1142 (2018)
- Dugel PU, "Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials", Clin Ophthalmol, 10, pp.1103~1110 (2016)
- Qu-Knafo LM, "Impact of serous retinal detachment on the efficacy of ranibizumab in diabetic macular oedema", Acta Ophthalmol, 95, pp.e434~5 (2017)
- Al-Latayfeh M, "Outcome of single dexamethasone implant injection in the treatment of persistent diabetic macular edema after anti-VEGF treatment : real-life data from a tertiary hospital in Jordan", Clin Ophthalmol, 15, pp.1285~1291 (2021)
- Hsia NY, "Short-term outcomes of refractory diabetic macular edema switch from ranibizumab to dexamethasone implant and the influential factors: a retrospective real world experience", Front Med(Lausanne), 8, pp.649979~ (2021)
- Gillies MC, "A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema : the BEVORDEX study", Ophthalmology, 121, pp.2473~2481 (2014)
- Hobbs S, "Proliferative diabetic retinopathy and diabetic macular edema: are these two different disease processes? A retrospective cross-sectional study", Invest Ophthalmol Vis Sci, 57, pp.1592~ (2016)